Adlai Nortye (ANL) Equity Ratio (2022 - 2025)

Adlai Nortye (ANL) reported Equity Ratio of 0.24 for Q4 2025, down 167.59% year-over-year from 0.36 in Q4 2024, and down 167.59% on a QoQ basis from 0.36 in Q4 2024.

Adlai Nortye (ANL) has 4 years of Equity Ratio data on file, last reported at 0.24 in Q4 2025.

  • Quarterly Equity Ratio fell 167.59% year-over-year to 0.24 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.24 (down 167.59% YoY) and the FY2025 annual result came in at 0.24, down 167.59% from the prior year.
  • Equity Ratio slipped to 0.24 in Q4 2025 per ANL's latest filing, from 0.36 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.58 in Q4 2023 and bottomed at 3.32 in Q4 2022.
  • The 4-year median for Equity Ratio is 0.36 (2024), against an average of 0.43.
  • The widest annual swing landed in 2023, when Equity Ratio jumped 117.34%; it then slumped 167.59% in 2025.
  • Tracing ANL's Equity Ratio over 4 years: stood at 3.32 in 2022, then jumped by 117.34% to 0.58 in 2023, then plunged by 37.97% to 0.36 in 2024, then tumbled by 167.59% to 0.24 in 2025.
  • Per Business Quant, the three latest ANL Equity Ratio figures stand at 0.24 (Q4 2025), 0.36 (Q4 2024), and 0.5 (Q2 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 0.04
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 0.42
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 0.73
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 0.77
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 0.21
10 Adlai Nortye 23,840.00 -8.03 Mn - -0.24

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -0.24
Dec 31, 2024 0.36
Jun 30, 2024 0.50
Dec 31, 2023 0.58
Dec 31, 2022 -3.32